Antibiotics for early stomach lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether antibiotics alone can treat early-stage stomach lymphoma that is not linked to H. pylori infection. The goal is to see if antibiotics can control the disease and avoid more intensive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have a confirmed diagnosis of early-stage gastric MALT lymphoma that has not spread far.
- Must have had no prior chemotherapy or radiation for this lymphoma.
- Must have proof of no H. pylori infection, based on all five tests being negative.
- Must have stage IE or IIE1 disease (lymphoma limited to the stomach or nearby lymph nodes).
- Must agree to provide tissue, blood, and stool samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
This study is looking at people with a rare stomach lymphoma (MALT lymphoma) or people with other stomach conditions. It aims to understand more about the disease and track outcomes over time.
This study tests a combination of a low dose of radiation and an oral targeted drug (orelabrutinib) for people with early-stage MALT lymphoma. The goal is to see if adjusting the treatment based on your response can be effective and reduce side effects.
This study tests whether artificial intelligence can help make radiation therapy more precise for stomach lymphoma. The goal is to improve treatment by adjusting the radiation plan each day based on your body's changes.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Hear when a new MALT Lymphoma of Stomach trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.